Startups
Fletcher Spaght is a strategy consulting firm focused on helping healthcare and technology companies increase revenue growth and their long-term potential.
Growth drives enterprise value. Management teams diligently pursue growth through both organic and inorganic alternatives. The risks associated with growth investments necessitate development of information critical to determining market receptivity, optimal strategy, the level of competitive advantage, successful customer engagement, and the impact of competitive response. Through in-depth primary research, rigorous analysis, and deep market knowledge, FSI delivers the detailed insights needed to inform critical business decisions that increase growth and enhance value.
Why Choose FSI?
FSI’s staff has the scientific and engineering background to understand the markets we serve; most of our professional staff has advanced degrees in science, medicine and/or engineering. FSI’s senior professionals began their consulting careers at strategy firms such as BCG and Bain. Building on staff experience and expertise, FSI has developed analysis tools, methodologies, and analytical approaches ensuring that we can efficiently support client needs. Senior staff actively participate in client work, bringing decades of market experience to help clients identify, evaluate, and act on achievable growth plans.
For over 30 years, FSI has:
• Helped clients with identifying, evaluating and planning how to grow their business
• Built a leading team staffed with professionals that specialize in disciplines within healthcare and technology
• Expanded its client-base to range from start-ups to the world’s largest companies, as well as leading venture capital and private equity firms
• Applied knowledge/experience associated with the high levels of innovation and growth in healthcare and technology to mature industry businesses seeking higher rates of growth
Growth drives enterprise value. Management teams diligently pursue growth through both organic and inorganic alternatives. The risks associated with growth investments necessitate development of information critical to determining market receptivity, optimal strategy, the level of competitive advantage, successful customer engagement, and the impact of competitive response. Through in-depth primary research, rigorous analysis, and deep market knowledge, FSI delivers the detailed insights needed to inform critical business decisions that increase growth and enhance value.
Why Choose FSI?
FSI’s staff has the scientific and engineering background to understand the markets we serve; most of our professional staff has advanced degrees in science, medicine and/or engineering. FSI’s senior professionals began their consulting careers at strategy firms such as BCG and Bain. Building on staff experience and expertise, FSI has developed analysis tools, methodologies, and analytical approaches ensuring that we can efficiently support client needs. Senior staff actively participate in client work, bringing decades of market experience to help clients identify, evaluate, and act on achievable growth plans.
For over 30 years, FSI has:
• Helped clients with identifying, evaluating and planning how to grow their business
• Built a leading team staffed with professionals that specialize in disciplines within healthcare and technology
• Expanded its client-base to range from start-ups to the world’s largest companies, as well as leading venture capital and private equity firms
• Applied knowledge/experience associated with the high levels of innovation and growth in healthcare and technology to mature industry businesses seeking higher rates of growth
Overview
Location
United States, Massachusetts, Boston
Employees
51-200
Founded date
1983
Mentions in press and media 16
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 25, 2013 | Roundup: Swift Biosciences Raises $7M Round, Free Wi-fi Now in Downtown Detroit | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Here’s a look at news from around Southeast Michigan’s innovation community: —Ann Arbor-based Swift Biosciences announced this week that it has raised a $7 million Series B ro... |
| Oct 18, 2013 | Swift Biosciences Raises $7M in Series B Financing | Swift Biosciences, an Ann Arbor, Michigan-based developer of technologies for genomics and personalized medicine, raised $7m in Series B financing. The round was led by Fletcher Spaght Ventures with participation from Renaissance Venture Ca... |
| Aug 21, 2012 | Type 2 diabetes drug with goal of 24/7 glycemic control begins Phase 2b trial | The biotechnology firm raised $48.4 million earlier this year in its third tranche for its series B financing round led by New Enterprise Associates with participation by Hatteras Venture Partners, Johnson & Johnson Development Corp., A... |
| Feb 14, 2012 | Cayenne Medical Closes $10M Equity Financing | Cayenne Medical, Inc., a Scottsdale, Arizona-based private sports medicine device company, closed a $10m equity financing. New investor Fletcher Spaght Ventures joined existing investors Split Rock Partners, MB Venture Partners and Investor... |
| Nov 15, 2011 | Hyperglycemia drug gets positive results in clinical trial | GLP-1 analogues that have been approved by the U.S. Food and Drug Administration need to be given at least once a day, said Lynne Georgopoulos, senior vice president of clinical development. “Our intent was to develop a long-acting drug tha... |
| Jul 9, 2011 | SurgiQuest Closes $19M Financing Round | SurgiQuest, Inc., an Orange, CT-based manufacturer of access technology for minimally invasive surgery, has closed a $19m round of financing. The round was led by River Cities Capital Funds, with participation from Fletcher Spaght Ventures,... |
| May 18, 2011 | Wound therapy startup SironRX on its way to $3M series A investment | SironRX got its start earlier this year with a $500,000 investment from Cleveland Clinic and Cleveland-based, state-backed venture development group JumpStart. The technology behind SironRX is also the basis for another company, Juventas Th... |
| May 18, 2011 | SironRX locks up $2.3 million funding round | Wound therapy startup SironRX Therapeutics has raised $2.3 million of a possible $2.5 million funding round. SironRx, which boasts technology pioneered at Cleveland Clinic, plans to use the funding to commence human trials, which the compan... |
| Dec 3, 2010 | Diabetes, cardiovascular drug developer PhaseBio adds $15M | Promoted Clinical Care Capacity Planning Learn how to manage clinical care capacity more efficiently during uncertain times. SAP Promoted Telemedicine’s potential to provide healthcare to the world’s most vulnerable Teladoc Health Head of R... |
Show more
Reviews 0
FAQ about Fletcher Spaght, Inc.
When was Fletcher Spaght, Inc. founded?
Fletcher Spaght, Inc. was founded in 1983.
What has the press written about Fletcher Spaght, Inc.?
Parsers VC has collected 16 articles mentioning Fletcher Spaght, Inc., among them “Roundup: Swift Biosciences Raises $7M Round, Free Wi-fi Now in Downtown Detroit” (Oct 25, 2013) and “Swift Biosciences Raises $7M in Series B Financing” (Oct 18, 2013).
Is Fletcher Spaght, Inc. still active?
Yes, Fletcher Spaght, Inc. is active; its latest activity on Parsers VC dates from Jul 22, 2014.